MIRM News and Press, Mirum Pharmaceuticals Inc. From 05/11/24

2024-05-11 14:25:17 ET Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Conference Call May 08, 2024, 04:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & C...

2024-05-08 17:07:42 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value Mirum Pharmaceuticals: Advancing On Several Key Fronts Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript ...

- First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million - FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March - Volixibat VISTAS and VANTAGE interim analyses scheduled for June of 2024 - Cash balanc...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Citizens JMP Life Sciences Conference in ...

- Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied - Significant improvements observed across multiple parameters including pruritus, serum bile acids, growth and bilirubin Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that dat...

Dallas, Texas--(Newsfile Corp. - May 2, 2024) - Stonegate Healthcare Partners is providing an update on the publication of its report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact o...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent corporate progress. Conference call details: Wednesday, M...

2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...